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Purpose: Agonistic b2-adrenergic receptor autoantibodies (b2-agAAbs) were recently
observed in sera of patients with ocular hypertension (OHT), primary (POAG), and
secondary open-angle glaucoma (SOAG), yet not in healthy controls (HCs). It was the
aim of the present study to investigate the presence of b2-agAAb in aqueous humor (AH)
samples of OAG patients and to correlate these with the corresponding b2-agAAb
serum data.
Material andMethods: Thirty-nine patients (21 male, 18 female) were recruited from the
Department of Ophthalmology, University of Erlangen-Nürnberg: twenty-one POAG, 18
SOAG. Aqueous humor samples were collected during minimal invasive glaucoma
surgery. Serum and AH samples were analyzed for b2-agAAb by a bioassay
quantifying the beating rate of cultured cardiomyocyte (cut-off: 2 U).
Results: Thirty-six of 39 (92.3%) and 34 of 39 (87.2%) of OAG patients showed a b2-
agAAb in their sera and AH samples, respectively. All b2-agAAb AH-positive OAG patients
were also seropositive. We also observed a b2-agAAb seropositivity in 95 and 89% of
patients with POAG and SOAG, respectively. Beta2-agAAbs were seen in 86% (POAG)
and 78% (SOAG) of AH samples. The b2-agAAb adrenergic activity was increased in the
AH of patients with POAG (6.5 ± 1.5 U) when compared with those with SOAG (4.1 ± 1.1
U; p = 0.004). Serum b2-agAAb adrenergic activity did not differ between the cohorts
[POAG (4.5 ± 1.5 U); SOAG (4.6 ± 2.1 U; p=0.458)]. No correlation of the beating rates
were observed between serum and AH samples for group and subgroup analyses.
Conclusion: The detection of b2-agAAb in systemic and local circulations supports the
hypothesis of a direct functional impact of these agAAbs on ocular G-protein coupled
receptors. The high prevalence of b2-agAAb in serum and AH samples of patients withorg May 2021 | Volume 12 | Article 5502361
Hohberger et al. Agonistic Autoantibodies in Glaucoma
Frontiers in Immunology | www.frontiersin.POAG or SOAG suggests a common role of these AAbs in the etiopathogenesis of
glaucoma, independent of open-angle glaucoma subtype.Keywords: autoantibodies, autoimmunity, glaucoma, aqueous humor, ß2-adrenergic receptorINTRODUCTION
Glaucoma is as neurodegenerative disease, one of the leading
causes for blindness in the developing countries. Its pathogenesis
is assumed to be multifactorial with an increased intraocular
pressure (IOP) as main risk factor. All therapeutic options—
either conservative, laser or surgical methods—aim to lower the
increased IOP up to an individual defined target level. Yet, all
patients show a disease progression despite an optimal level of
IOP (1). Thus, it is general accepted that several other factors are
involved in the complex multifactorial pathophysiology of
glaucoma. In addition to vascular dysregulation (2), oxidative
stress (3–5), and abnormalities of the lamina cribrosa (6) and the
trabecular meshwork (7), the involvement of autoimmune
mechanisms (8–10) are seen as risk factors.
In 2018 agonistic autoantibodies against the adrenergic b2
receptor (b2-agAAb) were initially identified in sera of patients
with ocular hypertension (OHT; n = 9) and primary open-angle
(POAG; n = 39) glaucoma, yet not in healthy controls (n = 17) (11). A
recent study showed the presence of these agonistic b2-agAAb in sera
of patients with secondary OAG (SOAG; n = 11) as well (12). The
presence of b2-agAAb in patients with OHT and OAG suggests a
fundamental involvement of these autoantibodies in the pathogenesis
of increased ocular pressure and glaucoma, respectively.
Beta2-adrenergic receptors (b2-ARs) were shown to be
present on non-pigmented epithelial cells of the ciliary body
(13, 14) and endothelial cells of the trabecular meshwork (14,
15), both involved in the regulation of IOP. These identified b2-
AR autoantibodies are directed against the second extracellular
loop of the G-protein coupled b2-AR. Due to the agonistic
activity of the b2-AAb, the b2-ARs are stimulated without showing
a receptor desensitization, usually observed using pharmaceutical b2-
AR agonists (e.g.Clenbuterol). Consecutively, the b2-AR is stimulated
chronically (12). We hypothesize that this chronic stimulation of the
b2-AR by b2-agAAb influences both the production of aqueous
humor (AH) by ciliary epithelial cells and the outflow resistance in
the trabecular meshwork (TM) resulting in an increased IOP.
The molecular pathway may be mediated by the Na-K-Cl co-
transporter in both ocular tissues. In TM the endothelial cell
volume is proposed to be regulated by Na-K-Cl co-transporter
(16). In vitro data support this assumption as cell volumes
changed after stimulation or inhibition of the Na-K-Cl co-
transporter (16). After hyperactivation of Na-K-Cl co-
transporter in TM cells osmotic changes might induce an
increased cell volume, consequently decreased extracellular
space and decreased outflow of AH. Data of Putney et al.
support this hypothesis, showing an increased volume of TM
cells in glaucoma patients (17). In the ciliary epithelium a non-
selective b2-AR blocker (isoproterenol) reportedly stimulates the
Na-K-Cl co-transporter (18) and, consequently, the chlorideorg 2transport (19). Moreover, AH flow was increased after
application of epinephrines (20). Thus, we assume that
hyperactivation of Na-K-Cl co-transporter in cells of the ciliary
body might induce an increased AH flow, as observed in eyes
with open-angle glaucoma especially at nighttime (21). This
hypothesis of an influence of b2-AAb on the increased IOP is
supported by in vivo data showing a decrease in IOP and/or
number of local antiglaucomatous eye drops after wash-out of
b2-agAAb by unspecific immunapheresis (12). As all recent
studies were based on b2-agAAb positivity, it would be of
interest if these agonistic autoantibodies would also be present
locally in aqueous humor (AH). A potential presence of b2-
agAAb in AH would support our hypothesis of a direct impact of
functional active b2-agAAb on ocular G-protein coupled
receptors (GPCRs). In addition, a potential hint for the
primary production of b2-agAAb might be offered via
correlation of AH and sera data. Thus, it was the aim of the
present study to investigate the presence of these b2-agAAbs in
AH samples of patients with OAG in correlation with their
corresponding serum data.MATERIAL AND METHODS
Patients
Thirty-nine subjects were recruited from the Department of
Ophthalmology, University of Erlangen-Nürnberg (21 male, 18
female): twenty-one POAG and 18 SOAG. Demographic data are
summarized in Table 1. All patients with OAG were under local
antiglaucomatous therapy and required a minimal invasive
glaucoma surgery (MIGS), as antiglaucomatous therapy was not
tolerated and/or IOP was not regulated under maximal local
antiglaucomatous therapy. Each patient underwent a complete
ophthalmological examination including measurement of best
corrected visual acuity and IOP, measured by Goldmann
applanation tonometry (Haag Streit, Koeniz, Switzerland). Slit-
lamp biomicroscopy of the anterior segment [configuration of the
anterior chamber angle, presence of melanindispersion and/or
pseudo-exfoliation (PEX)] was performed. Funduscopy was done
with grading of the optic disc according to the classification after
Jonas (22). Visual field was measured by standard white-on-white
full-field perimetry (Octopus 500, G1 protocol, mean defect, MD,
Interzeag, Schlieren, Switzerland). Additionally, global retinal
nerve fiber layer (gRNFL) was measured by Spectral Domain
Spectralis II OCT (Heidelberg Engineering, Heidelberg,
Germany). Serum and aqueous humor samples were acquired
during the same stay in the hospital. The study was approved by
the local ethic committee (53_14B) and performed according to
the tenets of the Declaration of Helsinki. Informed consent was
received from each patient, respectively.May 2021 | Volume 12 | Article 550236
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AH samples were obtained during MIGS. Before cutting the
corneal tunnel, aqueous humor samples were received via ab-
externo limbal paracentesis by a 27-gauge needle on a tuberculin
syringe. The samples were stored at −80°C.
POAG Eyes
Diagnosis of POAG was based on an open anterior chamber
angle, repeated (≥two times) measurements of increased IOP > 21
mmHg (measured with Goldmann applanation tonometry),
glaucomatous alterations of the optic disc [according to the
classification after Jonas (22)], and visual field loss (confirmed at
least once).
SOAG Eyes
Diagnosis of SOAG was based on an open anterior chamber angle,
repeated (≥two times) measurements of increased IOP > 21
mmHg (measured with Goldmann applanation tonometry),
glaucomatous alterations of the optic disc [according to the
classification after Jonas (22)], and visual field loss (confirmed at
least once). In addition, SOAG eyes showed melanindispersion in
the anterior chamber (melanin dispersion glaucoma) and/or PEX
material on structures of the anterior chamber (PEX glaucoma).
Cardiomyocyte Bioassay
The cardiomyocyte bioassay was performed as described previously
(12). Cell cultures of cardiac myocytes were established by digestion
of tissue samples (heart ventricle of 1–2 day-old Sprague–Dawley
rats) with a 0.25% solution of crude porcine trypsin (Serva,
Germany). The cells were dispersed and suspended in SM20-I
medium (Biochrom, Germany), containing glutamine (Serva,
Germany), streptomycin (HEFA Pharma; Germany), penicillin
(Heyl, Germany), hydrocortisone (Merck, Germany), 10% heat-
inactivated neonatal calf serum (Gibco, Germany), and
fluorodeoxyuridine (Serva, Germany). The cells were seeded at a
density of 160,000 cells/cm2. After 24 h the culture medium was
replaced. Before stimulation the cardiomyocytes were cultured for
3–4 days (37°C). 2 h before the experiment, the medium was
renewed. The sera and aqueous humor samples were dialyzed in
order to remove small bioactive components, which could
potentially be present in the sample. The dialysation did not
attach the IgG fraction. Afterwards the samples were applied
directly to the cardiomyocyte bioassay. This method was chosen
on the basis of a previous experiment. In a trial (n = 32) the
adrenergic activity, measured by the bioassay, was observed to beFrontiers in Immunology | www.frontiersin.org 3the same for IgG isolated (done by direct ammonium sulfate
precipitations described previously (12) and dialyzed sera (p =
0.179, t-test): adrenergic activity in the bioassay after applying IgG,
isolated by ammonium sulfate precipitations: 5.40 ± 0.28 U (after
incubation with ICI118.51 0.1 µM: 0.24 ± 0.06 U); adrenergic
activity in the bioassay after applying the dialyzed sera: 4.92 ± 0.21
(after incubation with ICI118.551 0.1 µM: 0.09 ± 0.05 U).
The beating rates of 7–10 spontaneously beating cardiomyocytes
were counted for 15 s at a heated stage inverted microscope (37°C).
An increase of 8 beats/s is considered 1 unit of adrenergic activity
(U). Samples below two units of adrenergic activity were considered
as normal.
Statistical Analysis
Statistical analysis was done by SPSS version 21.0 (IBM, New York,
USA). Data were presented as mean ± standard deviation. Data were
tested for normality previous to subsequent statistical analysis. Non-
parametric test was used for subgroup analysis of serum adrenergic
activity of b2-agAAb. T-test was used for subgroup analysis of AH
adrenergic activity of b2-agAAb. Additionally, Qui-quadrat test and
Pearson (for analysis of normal distributed data) and Spearman (for
analysis of non-normal distributed data) correlation analyses were
done for group and subgroup analyses. Demographic data were
analyzed by t-test, non-parametric test and Fisher exact test.RESULTS
b2-agAAb-Seropositivity
Beta2-agAAb-seropositivity was observed in 36 of 39 OAG
patients (92.3%). Mean beating rate of b2-agAAb seropositive
OAG patients was 4.60 ± 1.8 U. Subgroup analysis yielded a b2-
agAAb in 95% of sera of POAG and 89% of sera of patients with
SOAG (Figure 1). Beta2-agAAb seropositive POAG eyes showed
a mean beating rate of 4.5 ± 1.5 U. A mean beating rate of
4.6 ± 2.1 U was measured in b2-agAAb seropositive patients with
SOAG. No statistically significant differences were observed by
subgroup analysis (p = 0.458).
b2-agAAb AH-Positivity
Beta 2-agAAbs were found in 34 of 39 AH samples of patients
with OAG (87.2%). All patients (34/34) with b2-agAAb in their
AH were also seropositive (100%). Subgroup analysis yielded a
b2-agAAb AH-positivity in 86 and 78% of patients with POAG
and SOAG, respectively (Figure 1). No significant differencesTABLE 1 | Demographic data: age, gender, best corrected visual acuity (BCVA), intraocular pressure (IOP, mmHg), number of local antiglaucomatous eye drops, mean
defect (MD) and global retinal nerve fiber layer (gRFNL, µm) for open-angle glaucoma (OAG), primary OAG (POAG) and secondary OAG patients (SOAG);
mean ± standard deviation, p-value.
Total OAG POAG SOAG p-value
Age 69.72 ± 8.9 69.62 ± 7.5 69.83 ± 10.5 >0.05
Gender (female/male) 18/21 10/11 8/10 >0.05
BCVA 0.59 ± 0.2 0.58 ± 0.2 0.61 ± 0.2 >0.05
IOP 22.22 ± 7.5 22.30 ± 8.8 22.12 ± 5.8 >0.05
Number of local medication 2.59 ± 0.9 2.85 ± 1.1 2.29 ± 0.5 0.042
MD 11.38 ± 6.8 12.51 ± 6.9 9.96 ± 6.7 >0.05
Global RNFL 65.06 ± 20.4 60.85 ± 19.1 70.31 ± 21.3 >0.05May 2021 | Volume 12 | Article 550236
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with POAG and SOAG (p = 0.506).
A mean beating rate of 4.8 ± 2.4 U was measured in AH of b2-
agAAb AH-positive eyes from patients with OAG. Subgroup
analysis showed 5.9 ± 2.3 U and 3.6 ± 1.7 U in AH-positive eyes
from patients with POAG and SOAG, respectively. Accordingly,
b2-agAAb AH adrenergic activity was significantly increased in
patients with POAG as compared to those with SOAG (p = 0.001).
Association of b2-agAAb Adrenergic
Activity in Serum and AH
No statistically significant differences were observed for mean
beating rates of b2-agAAb seropositive and b2-agAAb AH-
positive OAG eyes (p = 0.202). Importantly, b2-agAAb
adrenergic activity in AH and the corresponding sera were
independent and did not correlate significantly (Spearman
correlation, Figure 2 and Table 2).
Subgroup analysis for b2-agAAb AH- and seropositive
patients with OAG yielded a significantly increased beating
rate in AH samples compared to serum samples in POAG (p =
0.001), yet only slightly in patients with SOAG (p = 0.043).
Further analyses did not show any significant correlation of b2-
agAAb beating rate of AH and serum samples (Table 2).
Association b2-agAAb Adrenergic Activity
With Clinical Glaucoma Parameters
Individual serum adrenergic activity of b2-agAAb did not show
any correlation with IOP, mean visual field defect, and global RNFL
thickness in group and subgroup analyses (Table 2), respectively.Frontiers in Immunology | www.frontiersin.org 4No significant correlations were to be observed for AH adrenergic
activity of b2-agAAb and IOP, mean visual field defect, and global
RNFL for group and subgroup analysis (Table 2).DISCUSSION
Autoimmune mechanisms are supposed to be involved in the
pathogenesis of glaucoma (23–25). Several studies support
the hypothesis of a contribution of immune mechanisms to the
complex interactions of glaucoma risk factors (11, 26, 27). Based on
previous observations of specific b2-agAAb in sera ofOAGpatients
and their potential involvement in IOP elevation (12), it was of
interest, to analyzewhether theseAAbs are alsopresent locally in the
AH. The data of the present study provide the first evidence for the
presence of b2-agAAb inAHof patients with OAG. Their presence
showed independent production of the AH antibodies since their
adrenergic activity did not correlate with the corresponding sera
data. Yet, glaucoma subtype seemed to be an influencing factor.
In the present study, b2-agAAbs were measured by an
established cardiomyocyte bioassay, which represents a direct
measure of AAb activity by alteration of the beating rate of
cultured cardiomyocytes. In addition to the mere detection of the
AAb, this technique enables testing their agonistic functionality.
The b2-agAAbs activate the b2-receptors and thus enhanced the
contractility of cultured cardiomyocytes. The time response
curve of theses b2-agAAbs continued for even 5 h without
desensitization, hereby leading to a substantial hyperactivation
of the b2-receptor (not shown) (12).FIGURE 1 | Agonistic activity of b2-agonistic autoantibodies.Stimulation of
cardiomyocytes by sera or aqueous humor samples from patients with OAG.
Open dots: POAG, filled dots: SOAG; normal range <2 units adrenergic
activity. Statistics: all POAG against all SOAG p = 0.035; all AH against sera
p = 0.96; POAG AH against sera p = 0.09; SOAG AH against sera p = 0.047;
AH POAG against SOAG p = 0.003; sera POAG against SOAG p = 0.727.FIGURE 2 | Correlation of the agonistic activities of b2-agonistic autoantibodies
in sera and aqueous humor. AH samples and corresponding sera of patients
with POAG (filled dots) or SOAG (open dots) are displayed. Note, the activity
values are mutually independent (p > 0.05, Spearman correlation).May 2021 | Volume 12 | Article 550236
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with OAG (12). The presence of these specific agonistic AAb in
AHmight support the above mentioned hypothesis of a regulatory
capability of IOP by the local b2-agAAb. All patients with OAG,
showing presence of b2-agAAb in AH, were also b2-agAAb
seropositive. This observation is in accordance with previous
observations of significantly increased Immunoglobulin G levels
in AH of an experimental autoimmune glaucomamodel (27). Two
candidate mechanisms underly this observation: (I) the b2-
agAAbs are either selectively imported into the eye alternatively;
(II) they are produced locally. Due to a significantly increased
agonistic activity in AH samples of POAG compared to those
from SOAG, the data might suggest that the b2-agAAbs are
produced locally in ocular tissues in POAG, yet, in SOAG the
b2-agAAbs in the AH are derived from serum. As b2-agAAb
adrenergic activity of AH and the corresponding serum turned out
to be independent, we tend to speculate that the AH-borne b2-
agAAbs are produced locally in ocular tissues.
Several autoimmune diseases show an involvement of extrafollicular
immune responses (e.g. systemic lupus erythematousus, SLE) (28).
Patients with SLE have an increased risk to develop glaucoma (adjusted
IRR 2.2) (29). Different mechanisms were discussed in this context: the
application of glucocorticoids (30), neuroendocrine-immune
pathogenic alterations (31), and ectopic germinal centers as niches
for antibody-secreting plasma cells (ASA) (28).
Canonical germinal centers are formed by B-cells after
antigen contact and T cell help. These activated B-cells migrate
to secondary lymphoid organs and pass the T-cell–B-cell border.
In the center of the follicle the B-cells initiate the formation of a
nascent germinal center (32). When these mature, they can
morphologically be divided into a souring light zone (LZ) and
inner dark zone (DZ). After somatic hypermutation (SHM) of
the immunoglobulin (Ig) in the DZ, the B-cells that have
developed high-affinity B cell receptors capture their specific
antigen on the surfaces of follicular dendritic cells, process it, and
present it CD4+ T helper cells (33). The affinity-maturated cells
then home to the bone marrow where they mature to plasma
cells that produce huge amounts of antibodies. It is discussed that
the Ig itself, the antigen-antibody complex or secondary
molecular cascades might be pathogenetic factors. Interestingly,
in chronically inflamed tissues non-canonical, ectopic germinal
center-like structures and tissue-borne plasma cells can develop.
The data of the present study might suggest that the b2-agAAbs
were produced locally in ocular tissues as the result of a local
ectopic germinal center formation. Further studies might follow
this hypothesis in order to visualize non-canonical germinalFrontiers in Immunology | www.frontiersin.org 5center-like structures in the ocular tissues of patients with
glaucoma. b2-agAAbs are one of several autoantibody species
(e.g. anti-HSP70, anti-vimentin) that have been detected in AH of
patients with glaucoma (27, 34, 35). The levels of the former AAb
could either be increased or decreased in patients.
Specific AAb patterns that reportedly depend on the
glaucoma subtype are under investigation (36). As b2-agAAb
adrenergic activity was observed in AH of POAG and SOAG and
as these did not correlate with the routine glaucoma follow-up
parameters, these data might indicate that b2-agAAb are
involved in very early stages of glaucoma pathogenesis by
shared pathophysiologic mechanisms. This hypothesis is
supported by the clinical finding that not all patients with
melanindispersion or PEX material show an increased IOP or
glaucoma characteristics during follow-ups. Thus, additional risk
factors are assumed to be involved in the pathogenesis of SOAG.
The study is not without limitations. Sample size is small;
thus, subsequent studies might follow this issue in a larger
patient cohort. In addition, it would be of interest, if these
autoimmune phenomena are also present in sera and/or AH of
glaucoma eyes of different ethnicities. As we are working on
setting up an assay to measure the b2-agAAb concentration,
correlation of the b2-agAAb level and routine glaucoma follow-
up parameters would be of interest, when available.
If subsequent studies could observe the presence of non-canonical
germinal center-like structures in ocular tissue of patients with
glaucoma, this local production of b2-agAAb could be the basis for
the development of a novel antiglaucomatous eye drop.CONCLUSION
The present study confirmed the high prevalence of b2-agAAb in
sera of patients with OAG and, for the first time reported their
presence in aqueous humor. A local production in the eye might
be supposed that the adrenergic activity in aqueous humor did
not correlate to those in their corresponding sera. The data of the
present study might suggest the contribution of a common
autoimmune response to the etiopathogenesis of glaucoma.DATA AVAILABILITY STATEMENT
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